# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-05T17:18:56.442962
**Route:** Direct Google API + PDF
**Paper Hash:** e0974276f44e1597
**Tokens:** 17798 in / 717 out
**Response SHA256:** a9c0c8cc6f1b5d54

---

I have reviewed the draft paper "Symbolic Legislation and Innovation Markets: The Effect of Right-to-Try Laws on U.S. Clinical Trials" for fatal errors.

### **1. DATA-DESIGN ALIGNMENT**
*   **Treatment timing vs data coverage:** The paper claims to study the staggered adoption of Right-to-Try laws between 2014 and 2018. The data panel covers 2008Q1 through 2017Q4. The author correctly identifies that the 2018 adopters (Nebraska and Wisconsin) are "effectively untreated" because their treatment starts after the sample ends.
*   **Post-treatment observations:** The paper utilizes the Callaway and Sant’Anna (2021) estimator. The text confirms that 36 states adopted within the sample period and have at least one post-treatment quarter.
*   **Consistency:** Table 5 (Adoption Timeline) aligns with the descriptions in Section 3.3 and the empirical strategy.

### **2. REGRESSION SANITY**
*   **Standard Errors:** Across Tables 2, 3, and 4, standard errors are in the range of 0.02 to 0.08. Given the outcome is $\ln(Y+1)$, these are standard and plausible.
*   **Coefficients:** Coefficients range from -0.09 to +0.06. These represent approximately -9% to +6% changes, which are highly plausible for the policy context.
*   **Impossible Values:** $N=2,040$ is consistent with a balanced panel of 51 jurisdictions $\times$ 40 quarters. All $p$-values and R-squared descriptions (where applicable via reference to TWFE) are within possible ranges. No "NA" or "Inf" values appear in the result tables.

### **3. COMPLETENESS**
*   **Placeholders:** No "TBD", "XXX", or empty cells were found in the tables. 
*   **Required Elements:** Sample sizes ($N$) are clearly reported in Table 1, Table 2, Table 3, and Table 4. Standard errors are provided in parentheses for all point estimates.
*   **Analyses:** All major analyses mentioned in the text (Callaway-Sant'Anna, TWFE, Placebo tests, Event Studies, Bacon Decomposition, Leave-one-out) have corresponding figures or tables.

### **4. INTERNAL CONSISTENCY**
*   **Numbers Match:** 
    *   Table 2 ATT for Trial Sites is -0.0039; text in Section 5.1 rounds this to -0.004.
    *   Table 2 ATT for Enrollment is -0.0626; text in Section 5.1 rounds this to -6.1% ($e^{-0.0626}-1 \approx -0.0607$).
    *   Table 2 ATT for Terminal Trials is 0.0690; text in Section 5.1 cites +6.9%.
*   **Timing:** The treatment window is consistent throughout the paper.
*   **Specifications:** Column headers and table notes accurately reflect the use of log-transformed counts and the specific estimators used.

**ADVISOR VERDICT: PASS**